Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Enanta Pharmaceuticals, Inc. (ENTA) had Normalized Income after Taxes of $-22.64M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$14.93M |
|
$-22.64M |
|
-- |
|
$14.93M |
|
$39.45M |
|
$-24.53M |
|
$0.58M |
|
$-23.95M |
|
$-23.95M |
|
$-22.64M |
|
$-22.64M |
|
$-22.64M |
|
|
Normalized Income after Taxes |
$-22.64M |
$-24.53M |
|
$-22.51M |
|
21.36M |
|
21.36M |
|
$-1.06 |
|
$-1.06 |
|
| Balance Sheet Financials | |
$242.86M |
|
$37.57M |
|
$80.13M |
|
$322.99M |
|
$45.95M |
|
-- |
|
$183.51M |
|
$229.46M |
|
$93.54M |
|
$93.54M |
|
$93.54M |
|
21.38M |
|
| Cash Flow Statement Financials | |
$-30.29M |
|
$64.53M |
|
$-11.87M |
|
$41.20M |
|
$63.57M |
|
$22.37M |
|
$10.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.29 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-164.32% |
|
-164.32% |
|
-- |
|
-160.45% |
|
-151.71% |
|
$-41.57M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
0.37 |
|
244.98 |
|
-24.21% |
|
-24.21% |
|
-7.01% |
|
-24.21% |
|
$4.38 |
|
$-1.95 |
|
$-1.42 |
|